Abstract
Methodology
Thirty-eight chronic Chagas disease patients (20 asymptomatic and 18 symptomatic) and twelve healthy controls were enrolled in this study. Peripheral blood mononuclear cells were stimulated with soluble T. cruzi antigens to analyze the production of cytokines and cytotoxic molecules by CD4 + CD8 + T cells before and after benznidazole treatment. Additionally, expression and co-expression of five inhibitory receptors in these patients after treatment were studied using a multiparameter flow cytometry technique.
Principal findings
The frequency of CD4 
Author summary
Chagas disease is a neglected tropical disease caused by the intracellular parasite Trypanosoma cruzi. The persistence of the parasite leads to deterioration of the host immune response, which is known as an exhaustion process. This process affects T cell populations, leading to increased expression of inhibitory receptors that leads to a dysfunctional ability to respond to the parasite. CD4 + CD8 + T cells form a poorly studied population of T cells in the context of Chagas disease. In this study, as in others previously reported, an increase in the frequency of these cells was observed in chronic Chagas disease patients. In addition, CD4 + CD8 + T cells from chronic Chagas disease patients underwent stronger exhaustion processes with more severe disease pathology. A higher level of expression and coexpression of inhibitory receptors was observed in these cells in symptomatic compared with asymptomatic patients. Furthermore, we evaluated whether antiparasitic treatment affected the population of CD4
Introduction
Even 100 years after Chagas disease was reported for the first time by Carlos Chagas, the infection remains an important public health problem in Latin America, with a high social and economic burden [1] and with a growing global impact [2] . The World health organization (WHO) estimates that approximately 8-10 million people worldwide are infected with Trypanosoma cruzi, the causal agent of Chagas disease, which causes approximately 20,000 deaths per year and is the leading cause of infectious myocarditis [3] . The main trypanocidal drug used to treat Chagas disease is benznidazole (BNZ). Side effects associated with BNZ therapy occurred in 30% to 87% of patients under the form of cutaneous, gastrointestinal or neurological disorders [4] [5] [6] . The effectiveness of BNZ during the chronic phase of the disease remains controversial. However, several studies have provided evidence supporting the benefit of BNZ during the chronic phase of Chagas disease based on its ability to improve the immune system capacity against the parasite [7, 8] and prevent the development of cardiomyopathy [9] [10] [11] . Moreover, the WHO as well as some systematic reviews recommend the use of antiparasitic treatment during the chronic phase of disease [12] [13] [14] [15] [16] . Taking all of this information into account, a key aspect to be considered in the fight against this disease is the need to identify biomarkers of therapeutic efficacy and their use as a new tool to facilitate the follow-up of treated patients [17] .
T. cruzi infection usually initiates with high parasitemia in blood that leads a strong immune response to partially control the infection, although it rarely resolves it completely. The parasite manages to hide in tissues that are less accessible to the immune response, resulting in infection chronicity [18] . Most patients maintain an asymptomatic chronic disease over years or even decades, but approximately 30-40% develop a symptomatic chronic phase [19] . In chronic infectious diseases, T cells undergo an important process known as cellular exhaustion [20] . The exhaustion process is produced by a continuous exposure to pathogen antigens that leads to a dysfunctional response of the T cells via an impaired ability to produce cytokines and cytotoxic molecules against the infectious agent, accompanied by a progressive increase in the expression and co-expression of inhibitory receptors on the membrane of antigen-specific T cells [20, 21] . The exhaustion process in Chagas disease occurs in CD8 + and CD4 + T cells [22, 23] and has been described be more dramatic during more severe stages of disease [23] .
Recently, anti-T. cruzi treatment has been shown to reduce this process of exhaustion in CD8 + T cells in chronic Chagas disease patients [24] . Circulating T cells are considered the key components of the adaptive immune system, and principally CD8 + and CD4 + T cells are the best described and known populations functioning in the control of T. cruzi infection [25] [26] [27] . Other T cells components require further studies to achieve a better understanding of their functions in the immune system, including CD4 + CD8 + peripheral T cells, which were described by Blue et al. as a population representing approximately 3% of lymphocytes in human blood [28] . Subsequent studies have characterized this cellular population in detail, but more information is still needed. Several groups have shown that CD4 + CD8 + T cells comprise mature T cells that are capable of being activated [29] [30] [31] [32] and able to respond to specific antigen-producing cytokines and cytotoxic molecules and to migrate to inflamed tissues [30] [31] [32] . Thus, their role has been studied in viral chronic infectious diseases such as HIV [29] and HCV [31] . 
Methods

Study population
This study enrolled 38 adult patients diagnosed with chronic Chagas disease (cChD). These patients were clinically characterized based on the Kuschnir classification of Chagas disease [34] and included 20 asymptomatic patients (IND) and 18 patients with heart damage (CCC) (G1, n = 8; G2, n = 6 and G3, n = 4). The patients were residents of Spain from endemic areas who were diagnosed with Chagas disease following WHO criteria based on two conventional serological tests (Chagas ELISA, Ortho Clinical Diagnosis and Inmunofluor Chagas, Biocientí-fica, Argentina) at the Hospital Virgen de la Arrixaca (Murcia-Spain) and who had never received any treatment for their disease. Patients with evidence of gastrointestinal disorders were excluded. All patients were treated with benznidazole 5 mg/kg/d for 60 days [35] , and clinical follow-up was performed during the entire 48-month study period. Twelve healthy donors (HD) were also included. During this study the patients did not show any clinical changes that could be associated with progression of Chagas disease.
Ethical considerations
The Ethic Committees from the Hospital Virgen de la Arrixaca, Murcia-Spain, and the Consejo Superior de Investigaciones Científicas (CSIC), Spain, approved the protocols used in this study. Signed informed consent was obtained from all individuals prior to their inclusion in the study.
Blood samples
Peripheral blood samples of 30 mL from each individual were collected by venipuncture into EDTA-containing tubes. Samples were collected prior to treatment administration (T0) and at two post-treatment times: after 9-12 months (T1) and after 24-48 months (T2). Peripheral blood mononuclear cells (PBMC) were purified as previously described [36] , stored in inactivated fetal bovine serum (iFBS) (Gibco, Grand Island, NY) with 10% DMSO and cryopreserved in liquid nitrogen until used.
DNA purification and PCR amplification
Genomic DNA purification from the peripheral blood samples and PCR amplification for parasite detection were performed as previously described by Murcia et al. [37] .
Isolation of T. cruzi soluble antigens
To obtain T. cruzi soluble antigens (TcSA), Rhesus Monkey Kidney Epithelial Cells (LLC-MK2 line; CCL-7, Manassas, VA) were cultured in RPMI-1640 supplemented with 2 mM L-glutamine (Gibco), 10% iFBS and 50 μg/mL gentamicin (Thermo Fisher Scientific, Waltham, Massachusetts, USA) at 37˚C in a humidified atmosphere with 5% CO 2 . The cells were grown until they formed a monolayer, which was infected with T. cruzi trypomastigote forms (MHOM/ BR/1950/ Y isolated strain) obtained from T. cruzi experimentally infected mice (parasite:cell ratio of 4:1). After 96 h, the parasites were recovered in trypomastigote and amastigote forms from infected-culture supernatants by centrifugation and subsequently washed with 1x PBS at pH = 7.2. Parasites were suspended at 1x10 6 parasites/μl in lysis buffer (50 mM Tris-HCl at pH 7.4, 50 mM NaCl, 0.005% NP-40, 1 mM PMSF, and 1 μg/mL leupeptin) and sonicated 3 times with pulses of 50-62 KHz for 40-s time intervals of 20 s. Soluble protein extracts were obtained by centrifugation at 10,000 rpm for 20 min at 4˚C. The protein concentration was determined using the micro BCA protein assay kit (Thermo Fisher Scientific), and the protein profile was analyzed by SDS-PAGE followed by Coomassie blue staining (Gibco).
Antibodies
The following conjugated Abs were used for cell surface staining: CD3-Pacific Blue (clone UCHT1), CD4-Alexa Fluor 700 (clone RPA-T4), CD8-APC-H7 (clone SK1), CD160-Alexa Fluor 647 (clone BY55), T-cell immunoglobulin and mucin-domain containing-3 (TIM-3)- Intracellular cytokine and cytotoxic molecules detection by flow cytometry assays in PBMC after stimulation with T. cruzi soluble antigens
PBMCs were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 10% iFBS and 50 μg/mL gentamicin. PBMCs were cultured at 1x10 6 cells/mL in the presence of anti-CD28
(1 μg/mL) and anti-CD49d (1 μg/mL) with TcSA (1 μg/mL) or without TcSA (considered the basal response). The cells were incubated for 10 h at 37˚C in a humidified atmosphere with 5% CO 2 , with the last 9 h in the presence of brefeldin A (1 μg/mL) and monensin (2 μM) (BD Bioscience). To evaluate intracellular cytokine production, at least 1x10 6 cells were stained for each condition. First, PBMCs were stained with a viability marker, LIVE/DEAD Fixable Aqua (Invitrogen, Eugene, OR), for 20 min in darkness at RT. The cells were stained with anti-CD3, anti-CD4, and anti-CD8 Abs. After washing, the cells were fixed and permeabilized with Cytofix/ Cytoperm (BD Biosciences). Intracellular staining was performed with anti-granzyme B, anti-IFN-γ, anti-IL-2, anti-TNF-α, and anti-perforin Abs for 30 min at 4˚C. Finally, 100,000 lymphocytes were acquired according to FCS/SSC parameters through a FACSAria III flow cytometer (BD Biosciences) for each condition. The data file was subsequently analyzed using FlowJo 9.3.2 software (Tree Star, Ashland, OR) to determine the percentages and mean fluorescence intensity (MFI) and to assess co-expression populations using a Boolean gating strategy. The gating strategy used is presented in S1 Fig. The positivity for each marker was determined using the fluorescence minus one (FMO) and isotype control stains. To obtain a robust data analysis, patients who at the time of pretreatment had a frequency of CD4 + CD8 + T cells greater than 0.3% and greater than 100 acquisition events for that population were selected for the study.
Identification of inhibitory receptor expression by flow cytometry
PBMCs were cultured in the same medium and under the same conditions as previously described for the cytokine detection assay. The cells were cultured in the presence of anti-CD28 and anti-CD49d and with TcSA (1 μg/mL) for 10 h. The cells were stained with the following cell surface Abs: anti-CD3, anti-CD4, and anti-CD8, anti-2B4, anti-CD160, anti-PD-1, and anti-TIM-3. After cell permeabilization, intracellular staining was performed with anti-CTLA-4 Ab. The cells were acquired and analyzed as described in the previous assay.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6.0 software (GraphPad Software, San Diego, CA). Nonparametric tests were used to test for statistical significance.
The Mann Whitney U test was used to carry out comparisons among patients and healthy donors or CCC and IND groups. The Wilcoxon test was used to study the post-treatment evolution. An additional analysis was performed to compare co-expression pie charts using 10,000 permutations calculated with SPICE version 5.3 software (the National Institutes of (Fig 1C and 1D) . Therefore, after treatment, the ratio of the frequency of CD4 + CD8 high /CD4 + CD8 low subpopulations from IND and CCC chronic patients tended to be similar to that detected in HD (Fig 1D) . (Fig 6B) . T. cruzi antigen-specific CD4 + CD8 + T cells from IND had a better multifunctional profile after treatment since there was a greater percentage of cells that produced 2 (27.2% to 30.5%), 3 (15% to 20.5%), 4 (3.6% to 5%) and 5 (0.2% to 1.6%) molecules in response to TcSA (Fig 6B) . CCC showed a significant increase in the proportion of T. cruzi antigen-specific CD4 + CD8 + T cells that produced 3 molecules (ρ = 0.013; 9.8% to 16.5%) ( Fig   6B) . However, the percentage of CD4 + CD8 + T cells that produced 4 molecules in response to TcSA decreased in CCC after treatment (3.1% to 0.7%). Moreover, after treatment, the Regarding the co-production of the cytokines IL-2 and IFN-γ (Fig 7A) (Fig 7B) . Moreover, CCC showed a stronger cytotoxic profile after treatment for the major proportion of T. cruzi antigen-specific CD4 
Results
Circulating population of CD4
Expression and co-expression of inhibitory receptors in the circulating
Parasite detection in the peripheral blood of Chagas disease patients by PCR
Before benznidazole treatment, T. cruzi DNA was detected in 11 out of 20 IND (55%) and 9 out of 18 CCC (50%). At the end of treatment and also 24 months after treatment, all these patients had a negative PCR result.
Discussion
A higher frequency of peripheral CD4 + CD8 + T cells has been described in several pathologies, such as chronic infections, versus healthy donors (HD) [39] [40] [41] . An increase in the frequency ) has been described to be derived from a group of terminally differentiated effector CD4 + T cells [40] . In the present study, the CD4 + CD8 low T cell subpopulation constituted a higher proportion in chronic Chagas disease patients compared with HD. Moreover, the subpopulation referred to as having high CD8 expression (CD8 high ) has been described as an activated population characterized by the expression of high levels of activation markers [43] . This CD4 In chronic diseases, the persistence of pathogen-derived antigens induces an increase in the expression of inhibitory receptors, and a gradual loss of the response capacity of antigen-specific T cells has been described. This process is known as an exhaustion process and has been observed in both CD4 + and CD8 + T cell population [44] . The exhaustion process occurs gradually, by step-wise, and includes the loss of the effector capabilities of the antigen-specific T cells together to the loss of self-renewal abilities related to the expression and co-expression of different inhibitory receptors. All this marks the degree of cell exhaustion, as a partial or severe process [44] . Interestingly, and for the first time, it is described that the population of CD4 + CD8 + T cells from Chagas disease chronic patients undergoes a similar exhaustion process to that previously described in CD8 + [23] and CD4 + T cells [22, 45, 46] + T cell exhaustion process observed in chronic chagasic patients could be associated with the T. cruzi antigenic persistence that occurs during the chronic phase of Chagas disease [47] . Indeed more than 50% of patients had a positive PCR result for parasite detection. The CD4 + CD8 + T cell population in symptomatic patients displayed increased TIM-3 expression, as well as an increase in a very small subpopulation that co-expressed 5 exhaustion molecules. This expression pattern could be indicating a possible positive correlation between the exhaustion process and the severity of disease. We suggest that the cellular exhaustion process and, consequently, the failure in the T-cell response could lead to the loss of parasite control and evolution of the disease towards the symptomatic phase. In chronic viral infections, greater expression of inhibitory molecules by T cell is positively correlated with severe exhaustion and usually with the viral burden [44] . reported that the CD160 expression improves proliferation and cytotoxic activity of CD8 + T cells [50] . It has been proposed that an elevated expression of CD160 and 2B4 delineated a population of cytolytic CD8 + T cells relevant for the control of HIV [51] . Moreover, IFN-γ secretion by NK cells was markedly reduced in CD160 (-/-) mice [52] . Consequently, it can be hypothesized that IND patients exhibit greater expression of CD160 mainly due to the relatively high proportion of CD4 while the IL-2 production increased. In this sense, it has been described that CD160 molecule acts as inhibitory receptor independently of PD-1 and its blockage leads to the improvement of the IL-2 production by CD8 + T cells in chronic HIV [53] . In contrast, after treatment, the percentage of CD4 + CD8 + T cells expressing CTLA-4 increased in CCC. For the latter reason, the increased numbers of cells expressing CTLA-4 was not associated with the enhancer of the cellular exhaustion process. It is assumed that this increase is related to an increase in regulatory function because this marker is fundamental for appropriate immune homeostasis [54] . These results support that benznidazole treatment reverses the exhaustion process, as previously described in CD8 + T cells in chronic patients [24] . Furthermore, the observed pattern of the frequency of CD4 + CD8 + T cells from Chagas disease patients, expressing some inhibitory receptor is similar to that reported by the CD8 + T cells [23] . Otherwise, some differences in the frequency patterns of CD4 + CD8 + versus CD8 + T cells expressing inhibitory receptors was observed depending on the state of disease severity. Thus, the IND had a higher percentage of CD4 + CD8 + T cells expressing CD160 or 2B4 than that observed in CCC, which was not found in the CD8 + T cells [23] . In this context, it has been described that the pattern of co-expression of inhibitory receptors and the number of receptors simultaneously expressed by the same CD8 + T cells from patients with chronic viral (HIV) infection can substantially affect the severity of dysfunction [55] . Moreover, in HIV patients the CD160 was expressed by a low percentage of exhausted CD8 + T cells and always associated with co-expression of other inhibitor receptors [55] . It is interesting that the treatment with benznidazole increased the subpopulation of CD4 + CD8
high T cells while simultaneously reduced the CD4 + CD8 low T cell subpopulation. parallel to the decrease in inhibitory receptors co-expression, which could be related to reversion of the T-cell exhaustion process and, thus, improvement of the cellular functionality against the parasite-derived antigens. Interestingly, the recovery of cytokine production in CD4 + CD8 + T cells occurred in a stepwise manner in an order opposite to that observed during the T-cell exhaustion process, in which cytokine production was lost in the following order: IL-2>TNF-α>IFN-γ [63, 64] . Thus, our results showed that after treatment, IL-2 production was recovered in both IND and CCC, TNF-α production was recovered in IND and started to recover in CCC, and IFN-γ production started to recover in IND. . A cytotoxic profile that co-expresses both molecules (perforin and granzyme B) combined with cytokine production has been described for CD8 + T cells in patients with a mild form of Chagas disease [23] . This multifunctional profile is enhanced after benznidazole treatment in CD8 + T cells [24] .
The analysis of the parasite load in the peripheral blood showed presence of the parasite in approximately 50% of the patients independently of the phase of the disease. At the end of the treatment and 24 months after treatment all patients presented a negative PCR result. According to the PCR data obtained in this study, are those previously reported that support the effect of the benznidazole on the reduction of the parasite load [12] . In spite of that, and the fact that a PCR positive result is consistent with treatment failure, a negative PCR cannot be associated to treatment success [47] . Consequently, neither the obtained data regarding to the parasite load detected by PCR nor the existence of clinical changes associated to progression (or not) of the sickness in these patients allowed to evaluate the efficacy of benznidazole treatment.
In summary, these findings suggest that CD4 + CD8 + T cells could be an important component of the immune response against T. cruzi infection during the chronic phase of Chagas disease. These cells are able to produce a multifunctional response against the parasite and undergo an exhaustion process associated to a long period of coexistence of the parasite with its host. These findings reflected in this work, shed light on the understanding of a population that is poorly described at a functional level in the context of Chagas disease. 
